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related myocardial edema.1-5 We have shown previous-
ly that myocardial edema is present clinically in cardiac
allograft rejection6 and that crystalloid coronary perfu-
sion results in edema and predictable commensurate
impairment of myocardial filling.7 The impaired left
C ardiac transplantation is an accepted mode of thera-py for end-stage heart disease; however, allograft
rejection continues to be an obstacle to long-term sur-
vival. Recent studies have demonstrated the role of
nitric oxide in allograft rejection, graft function, and
Objective: Inhibition of inducible nitric oxide synthase (nitric oxide II) activ-
ity has been proposed as a method to attenuate capillary leak and edema dur-
ing rejection of heterotopically transplanted rat hearts. Myocardial edema
has previously been implicated in diastolic dysfunction during allograft
rejection. Accordingly, we tested the hypothesis that inducible nitric oxide
synthase inhibition with aminoguanidine would alleviate left ventricular
stiffening and myocardial edema formation in 4-day heterotopic rat heart
allografts.
Methods: Passive left ventricular filling was studied in American Cancer
Institute Lewis rats receiving heterotopic heart transplants receiving either
aminoguanidine, a selective nitric oxide synthase inhibitor (n = 6); dexa-
methasone (1 mg · kg–1 · d–1 administered subcutaneously) for 4 days after
transplantation (n = 6); or intravenous saline solution (n = 6). American
Cancer Institute–to–American Cancer Institute isografts (n = 6) were used as
controls.
Results: Serum nitrite/nitrate levels in the aminoguanidine group (18 ± 3
mmol/L) and dexamethasone group (22 ± 4 mmol/L) were reduced versus
the intravenous saline group (144 ± 36 mmol/L [SEM]) to levels seen in con-
trols (25 ± 9 mmol/L). Left ventricular volume at 15 mm Hg for the
aminoguanidine group was increased versus that for the intravenous saline
solution group, similar to that for controls, and reduced versus dexametha-
sone-treated animals. Myocardial water content for the aminoguanidine-
treated animals (78.3% ± 0.4%) was similar to those of intravenous
saline–treated animals (78.0% ± 0.3%) but greater than those of controls
(77.1% ± 0.2%) and dexamethasone-treated animals (76.7% ± 0.3%).
Conclusions: Nitric oxide II inhibition with aminoguanidine minimizes the
reduction in left ventricular filling that is seen with allograft rejection
through a mechanism that is not associated with attenuation of myocardial
edema.  (J Thorac Cardiovasc Surg 2000;120:39-46)
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ventricular (LV) filling that is seen in the rejecting car-
diac allograft, however, is incompletely explained by
myocardial edema.8 In the present study, the inducible
nitric oxide synthase (iNOS, NOS II) inhibitors
aminoguanidine and prednisone were used to further
delineate the importance of edema in diastolic abnor-
malities associated with rejection in rat heart transplan-
tation.
Methods
Heterotopic rat heart transplantation. All animals
received humane care in compliance with the “Principles of
Laboratory Animal Care” formulated by the Institute of
Laboratory Animal Resources and the “Guide for the Care
and Use of Laboratory Animal Resources” prepared by the
Institute of Laboratory Animal Resources and published by
the National Institutes of Health. Male ACI and Lewis rats
were purchased from Harlan Sprague-Dawley (Indianapolis,
Ind). Heterotopic abdominal heart transplantation was per-
formed in either ACI-Lewis allografts or ACI-ACI isografts
by the technique of Ono and Lindsey9 and modified as previ-
ously described.8 In brief, donor hearts were arrested with
cold (4°C) University of Wisconsin solution and stored in the
arrest solution while the recipient animal was prepared. Total
ischemic time was kept at less than 30 minutes to minimize
the effects of ischemic contracture. After the induction of
anesthesia with ketamine (80 mg/kg) and aseptic preparation
of the recipient animal with iodine solution, a midline abdom-
inal incision was made, and the donor aorta and pulmonary
artery were anastomosed to the recipient abdominal aorta and
inferior vena cava, respectively. The abdominal incision was
then closed, and the animals were allowed to recover.
Animals were fed a standard diet of water and rat chow ad
libitum.
Experimental groups. Four experimental groups were
studied: ACI, ACI isografts (n = 6), intravenous saline–treat-
ed ACI-Lewis allografts (n = 6), aminoguanidine-treated allo-
grafts (n = 6), and dexamethasone-treated allografts (n = 6).
Immediately after transplantation, intravenous saline–treated
ACI-Lewis allograft rats underwent cannulation of the exter-
nal jugular vein with a plastic catheter that was connected to
an ALZA osmotic infusion pump (Alza Corp, Palo Alto,
Calif) loaded and primed with 0.9% normal saline solution
and implanted in the subcutaneous space. Aminoguanidine-
treated animals were prepared in the same way; however,
osmotic pumps were loaded with aminoguanidine hemisul-
fate (Sigma Chemical Co, St Louis, Mo) dissolved in 0.9%
normal saline solution (400 mg/mL). Dexamethasone-treated
animals received similar osmotic pumps loaded with dexa-
methasone, which was administered subcutaneously without
a catheter at a rate of 1 mg · kg–1 · d–1. Isografts did not under-
go pump implantation and were not treated. On post-trans-
plantation day 4, animals were again anesthetized, and serum
was obtained from the external jugular vein for determination
of nitrite-nitrate levels. Both transplanted and native hearts
were arrested with University of Wisconsin solution, excised,
and assessed for LV pressure-volume rejection, myocardial
water content, and histology.
Chemiluminescent determination of serum nitrite-
nitrate. External jugular venous blood was centrifuged to
remove red blood cells, and aliquots of the remaining serum
were reduced to nitric oxide (NO) by using acidic vanadium
chloride. Subsequently, the NO was allowed to react with
ozone in the reaction chamber of a nitric oxide analyzer
(model 280, Seivers). The resultant chemiluminescence is
directly proportional to the amount of NO introduced.10
Determination of the LV pressure-volume relation.
Excised hearts were instrumented with a 16-gauge Angiocath
catheter (Becton Dickinson, Franklin Lakes, NJ) stopcock,
and 5F micromanometer as described previously.8 University
of Wisconsin solution was infused in 0.02-mL aliquots until
an LV pressure of greater than 20 mm Hg was reached. The
operator performing the volume infusion (C.-X.J.) was blind-
ed to the group assignment of each heart under study.
Pressure-volume data were analyzed as described previous-
ly.8 The mean curve was calculated for each animal by aver-
aging ventricular pressures corresponding to the volume
injected.
Myocardial water content. After determinations of LV
pressure volume relationship (LVPVR) and removal of the
atria, hearts were gently blotted dry, placed on a
preweighed piece of foil, and weighed on an analytic bal-
ance (model H16; Mettler-Toledo, Hightstown, NJ). Next,
hearts were bivalved through both ventricles, and a hemi-
cross section was excised and placed in 4% formalin for
histologic study. The remainder of the specimen was again
weighed before and after drying for 48 hours in a 60°C
oven. Myocardial water content was calculated according
to the following equation:
Myocardial water content (%) = 100 × (WHW –
DHW)/WHW
where WHW is the wet heart weight and DHW is the heart
weight obtained after drying.
Histology.  Cardiac cross-sectional samples comprising
portions of both left and right ventricles were fixed overnight
in 4% formalin, embedded in paraffin, sectioned, and stained
with hematoxylin and eosin. Each slide was graded by a
blinded observer for International Society of Heart and Lung
Transplantation11 rejection grade as follows: rejection grade
0:0, 1A:1.0, 1B:1.5, 2:2.0, 3:3.0, 3B:3.5, 4:4.0.
Statistical analysis. So that LVPVR between animals of
different body weights (W) could be compared, LV raw vol-
umes (V) were normalized (Vn) to a body weight of 273.5 g
(mean weight for the series) by the following equation7:
Vn = V (273.5/W)
Pressure-volume data were generated by infusing incre-
mental volumes of fluid into the LV cavity. The data were
analyzed by averaging all of the LV volumes that fell within
predefined pressure ranges. For the purposes of analysis, the
pressure is treated as the independent variable, and the vol-
ume is treated as the dependent variable, even though it was
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the volume that was manipulated experimentally. Pressure-
volume data were analyzed by 2-way repeated-measures
analysis of variance (ANOVA), with mean normalized vol-
ume within each of 5 pressure ranges averaging 0, 5, 10, 15,
and 20 mm Hg as the repeated measure and experimental
group as the grouping factor. If significance was found for the
group effect or the group-by-pressure interaction, post hoc
comparisons of volumes at each pressure range were made
among the groups by using the Tukey procedure with a
Bonferroni adjustment for the number of comparisons. Mean
serum nitrite/nitrate levels and myocardial water content
were calculated and compared between experimental groups
by 2-way ANOVA and the Tukey posttest.
Mean body weights were compared between groups by 1-
way ANOVA. Mean percentage myocardial water content
were compared by 1-way ANOVA with post hoc compar-
isons performed by a Bonferroni procedure. Mean edema
grades and rejection grades were compared by the Kruskal-
Wallis nonparametric ANOVA. Least squares linear regres-
sion analysis was performed between individual percentage
myocardial water content values and edema grade.
Significance in all cases was defined as a P value of less
than .05.
Results
Reduction in serum nitrite levels in animals treated
with dexamethasone and aminoguanidine was mea-
sured by serum nitrite to nitrate levels (NO2/NO3).
After 4 days of reperfusion, NO2/NO3 in the intra-
venous saline–treated ACI-Lewis allograft group
(144 ± 36 mmol/L) was significantly elevated when
compared with isografts (25 ± 9 mmol/L, P < .05),
dexamethasone-treated animals (22 ± 4 mmol/L, P <
.05), and aminoguanidine-treated animals (17.5 ± 2.6
mmol/L, P < .05).
The effects of treatment group on the diastolic LVPVR
in transplanted and native hearts, respectively, are
demonstrated in Figs 1 and 2. For transplanted hearts
(Fig 1) at pressure intervals averaging 5 and 15 mm Hg,
the allograft group had significantly lower filling vol-
umes than the other 3 groups (aminoguanidine, dexa-
methasone, and isografts; P < .05). Dexamethasone-
treated animals had significantly higher filling volumes
at all pressure intervals compared with the allograft and
aminoguanidine-treated animals (P < .001). Filling vol-
umes in the transplanted hearts were considerably lower
than in the native hearts (Fig 2).
The effect of treatment group on myocardial water
content is illustrated in Fig 3. Aminoguanidine-treated
animals (78.3% ± 0.4%) were similar to the allograft
group (78.0% ± 0.03%) but significantly greater than
the isograft group (77.1% ± 0.2%) and dexamethasone-
treated animals (76.7% ± 0.3%, P < .05).
The effect of treatment group on allograft rejection
score was assessed. Dexamethasone-treated animals
had a significantly lower score (0.0 ± 0.0) than the allo-
graft group (3.3 ± 0.3, P < .001) and the aminoguani-
dine-treated animals (2.7 ± 0.4, P < .05).
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Fig 1.  The effect of post-transplantation treatment on diastolic pressure volume curves is demonstrated. At pres-
sure intervals averaging 5 and 15 mm Hg, allografts had significantly lower filling volumes versus the 3 other
groups (aminoguanidine [AG], dexamethasone [Dex], and isografts; P < .05). Dexamethasone-treated animals had
significantly higher filling volumes at all pressure intervals compared with isografts and aminoguanidine-treated
animals (P < .001).
Representative hematoxylin and eosin–stained pho-
tomicrographs of the experimental groups are displayed
in Fig 4. Fig 4, A, shows histologic characteristics of an
unmodified isograft displaying relative scarcity of inter-
stitial infiltrate. Fig 4, B, is an unmodified allograft
showing extensive mononuclear cell interstitial infiltra-
tion. Fig 4, C, is an aminoguanidine-treated allograft
showing mononuclear cell interstitial infiltration and
increased fiber separation consistent with myocardial
edema. Fig 4, D, is a dexamethasone-treated allograft
showing no cellular infiltrate and close apposition of
fibers.
Discussion
The constitutive endothelial form of NO synthase
(cNOS, NOS III) is calcium dependent, and NO pro-
motes vasorelaxation. Activity of the inducible form of
NO synthase (iNOS, NOS II) is not modulated by ambi-
ent calcium levels, is not present under basal conditions,
and is induced by rejection and inflammatory media-
tors. Increased myocardial NOS II messenger RNA,
protein, and enzyme activity have been reported in the
rejecting heart. Attenuation of this effect of rejection has
been achieved previously with immunosuppressive
agents, including corticosteroids, cyclosporine (INN:
ciclosporin), and FK506.4 Worrall and colleagues5
demonstrated that specific inhibition of NOS II with
aminoguanidine attenuated the histologic changes asso-
ciated with rejection while minimizing increased capil-
lary permeability and myocardial edema.
The present results augment understanding of the
relationship between NOS II and the diastolic proper-
ties of transplanted hearts. We demonstrate increased
serum NO2/NO3 levels on day 4 in controls and that
steroid immunosuppression on day 4 reduces NO2/NO3
expression while increasing LV filling volume and
reducing myocardial edema. Aminoguanidine similarly
suppresses NO2/NO3 levels without significantly
reducing myocardial edema. LV filling volume, how-
ever, increases versus that of controls to a smaller
extent with aminoguanidine than with dexamethasone.
Aminoguanidine does not reduce lymphocyte infiltra-
tion, as measured by the histologic rejection score.
Finally, steroids are found to suppress all manifesta-
tions of rejection while resulting in diastolic properties
superior even to those observed in isografts.
Native heart pressure volume curves were right shift-
ed compared with transplanted hearts, including iso-
grafts. Isografts were less compliant than native hearts.
Processes in the transplanted hearts that could account
for these observations include atrophy because of
unloaded state, myocardial edema, or ischemic con-
tracture. Further work is needed to establish the relative
importance of each of these processes in this model.
Previous studies of diastolic properties in the arrest-
ed heart indicate that ischemic contracture and myocar-
dial edema are the predominant causes of impaired
diastolic filling in the arrested left ventricle. However,
the present results require an additional mechanism to
explain the observed effects of aminoguanidine on fill-
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Fig 2. Postmortem LVPVRs for native hearts. No significant differences in normalized LV volume were found
among groups. AG, Aminoguanidine; Dex, dexamethasone.
ing volume. Yuan and colleagues12 demonstrated that
nitric oxide produced by NOS III augments endothelial
monolayer barrier function, preventing retraction of
lateral margins of component cells. This prevents para-
cellular leakage and unrestricted diffusion. Local
induction of NOS II in the cardiac allograft in cardiac
myocytes and infiltrating macrophages13 produces
toxic effects and cellular destruction.14 Thus NOS II
induction and associated augmented NO generation
should increase edema in rejecting cardiac allografts.
However, no beneficial effect of aminoguanidine, a
relatively selective inhibitor of NOS II, on myocardial
water content was observed, although serum NO and,
presumably, NO generation were reduced. Although it
is possible that systemic NO was depressed and local
NO was not, this is inconsistent with the observation
that aminoguanidine reduces the severity of rejection.5
One possible explanation for the present findings is that
local release of lysosomal enzymes, complement, and
toxic oxidants by recruited leukocytes is the primary
determinant of endothelial cell damage and edema in
rejection. If this is true, NOS II–mediated effects on
edema could be overwhelmed by local toxic reactions.
Alternatively, nitric oxide is continually produced in
the normal heart,15 where it appears to participate in
autoregulation of both myocardial inotropy and
lusitropy. Recent studies including work by Grocott-
Mason and colleagues16 have shown that NO hastens
active myocardial relaxation or lusitropy. However, it is
important to distinguish lusitropy (active, ATP-depen-
dent, early diastolic relaxation) from passive myocar-
dial stiffness properties as measured by postmortem
pressure volume curves in this study, which would
exhibit greater correlation with late diastolic function
or compliance. Lewis and coworkers17 found that
increased NOS II messenger RNA expression by
means of reverse transcription–polymerase chain reac-
tion correlated with worsened diastolic function by
means of Doppler echocardiographic criteria in 16
patients during the first year after cardiac transplanta-
tion.17 These effects may be mediated by alterations in
calcium sensitivity of the contractile elements or alter-
ations in phospholamban-mediated calcium reseques-
tration. In any case, these local modulatory influences
appear to be calcium-dependent and related to NOS III
activity within the endocardium and microvascula-
ture.14 Increased local NOS II production (or its inhibi-
tion by aminoguanidine) could result in dysregulation
of the homeostatic role of NOS III in normal cardiac
lusitropy by either direct or indirect mechanisms.
Evidence for interaction between these two isoforms
exists in other model systems. For example, Schwartz
and coworkers18 concluded that NO autoinhibition
mediates NOS II-NOS III interaction in the kidney in a
rat sepsis model.18
Aminoguanidine, by inhibiting NOS II and reducing
local inflammation, could minimize tissue reaction to
the graft and fibrosis. This hypothesis is supported by
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Fig 3.  Myocardial water contents for each group. Aminoguanidine (AG)–treated animals (78.3% ± 0.4%) had sim-
ilar levels as allografted animals (78.0% ± 0.03%) but significantly greater levels than those of isografted animals
(77.1% ± 0.2%) and dexamethasone (Dex)–treated animals (76.7% ± 0.3%, P < .05).
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Fig 4. Representative photomicrographs of the experimental groups. A, Isograft myocytes showing relative paucity of
interstitial infiltrate. B, Allograft myocytes showing extensive mononuclear cell interstitial infiltration. C,
Aminoguanidine-treated myocytes showing interstitial mononuclear cell infiltration and increased fiber separation con-
sistent with myocardial edema. D, Dexamethasone-treated myocytes with no cellular infiltrate and decreased interstitial
separation consistent with the absence of myocardial edema.
A B
C D
the observed effects of steroid administration (which
reduced nitrates and water content to isograft levels),
normalized rejection score, and eliminated cellular
infiltrates. Most important, steroids enhanced filling
volume in the allografts to levels superior to those
observed even in the isografts. This strongly suggests a
generalized effect on fibrosis after ischemic damage at
the time of transplantation or on reactive fibrosis at the
epicardial surface. With specific respect to compliance
in the steroid group, blunting of the inflammatory reac-
tion in the peritoneum after the transplant procedure
may have reduced pericardial inflammation and reac-
tive pericardial fibrosis, causing pressure-volume
curves in this group to shift further toward those of
native hearts. Active fibrosis has not been demonstrat-
ed to effect alterations in the pressure-volume relation
of the heterotopic isograft, but this could be a factor in
this model. Fibrous tissue content was not scored or
quantified in the present study, but this may be incor-
porated into future work on this model. In this scheme
we hypothesize two processes adversely affecting dias-
tolic properties of the heterotopic allograft. The first is
rejection, which is inhibited to a variable degree by
NOS II suppression. The second is fibrosis, which is
mediated in the myocardium by inflammation caused
by ischemia and reperfusion at the time of surgery and
mediated at the epicardial surface by local reaction to
surgery. Because all transplanted hearts had reduced
filling volumes versus native hearts, it is also possible
that myocardial protection during the ischemic period
and during reperfusion was inadequate, resulting in
diastolic dysfunction. Other performance parameters,
such as heart rate, were not assessed in this protocol.
In contradistinction to these data, Worrall and
coworkers1 found that aminoguanidine inhibition of
NOS II in allografts reduced myocardial edema when
compared with controls; compliance was not measured
by Worrall and coworkers. Differences between the
data from this study and those from work by Worrall
could be accounted for by numerous experimental fac-
tors. That group used wet/dry weight ratios to assess
myocardial water content, whereas we used the per-
centage of myocardial water content. Worrall’s group
used topical iced saline solution to effect cardiac arrest,
whereas we used intracoronary University of
Wisconsin solution to induce arrest, and myocardial
protection strategy can alter the percentage of myocar-
dial water content.19 Differences in tissue processing,
including blotting, trimming of RV and atrial tissues,
and drying protocols, might also alter results.
Correlation of our study with Worrall’s data empha-
sizes that two pathways of aminoguanidine NOS II
inhibition of diastolic dysfunction may exist in the het-
erotopic cardiac transplant model, one dependent on
myocardial edema and one independent of myocardial
edema. Indeed, recent data indicate that NO triggers
programmed cell death (ie, apoptosis) of adult rat ven-
tricular myocytes.20 Apoptosis triggers cell death by
means of a noninflammatory mechanism; its suppres-
sion (through NOS II inhibition) might theoretically
preserve compliance. The duration of the current obser-
vation period (4 days) is not sufficient to make long-
term compliance assessment, which may change with
fibrosis and delayed cellular infiltration. However, by 4
days, NOS II blockade does preserve compliance in the
present study.
In summary, suppression of NOS II with
aminoguanidine restores diastolic properties of reject-
ing allografts to levels comparable with those of iso-
grafts but does not eliminate myocardial edema or his-
tologic manifestations of rejection. Steroid suppression
normalizes all manifestations of rejection except for
diastolic properties, which are rendered superior to
those of isografts, approaching levels appreciated in
native ventricles. These observations are consistent
with the view that abnormalities of diastolic properties
in heterotopic allografts and isografts involve rejection,
as well as fibrosis related to ischemia and reperfusion
at surgery and reaction at the interface of the epicardi-
um and surrounding tissues. Inhibition of NOS II
appears to favorably affect both sources of abnormali-
ty of diastolic properties.
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